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Summary
A quantitative structure toxicity relationship (QSTR) is proposed to correlate 
the toxicity of drugs on rat after intravenous administration. The computational 
descriptors of 319 drug molecules are calculated using HyperChem software and 
regressed against LD50 of drugs collected from the literature. Correlation coefficient 
(R), F value and average percentage deviation (APD) between calculated and experi-
mental LD50 are used to evaluate the accuracy of the proposed QSTR model. The 
best QSTR model is:
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where, SAA is surface area (approximate), VOL molar volume, HE hydration 
energy, log P is the logarithm of partition coefficient, REF molar refractivity, POL 
polarizability, MASS molecular weight, TE total energy and HOMO energy of the 
highest occupied molecular orbital. The APD of a number of drugs are very high and 
this resulted in high APD for the data set. These drugs include busulfan, calcitriol, 
epinephrine, triaziquone etc. and could be considered as outliers. After excluding 
these data points, the model is:
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Small changes in the model constants showed that the model is robust and could be 
considered as a predictive model. Because of various toxic mechanisms, high discrep-
ancy in reported LD50 of some drugs from different references, high APD value 
could be justified. As an example, LD50s of dixyrazine are 37.5 and 3.75 in different 
references. After excluding the outliers, APD reduces to 977%. The APD could 
be considered as acceptable over range if the experimental discrepancies between 
reported LD50 from different laboratories are kept in mind.
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Resumen
Una correlación cuantitativa entre la estructura molecular de 
fármacos y la toxicidad en ratas
En este trabajo se plantea una correlación cuantitativa entre la estructura molecular 
de fármacos y la toxicidad (QSTR) en ratas después de la administración intrave-
nosa. Se calcularon los descriptores computacionales de la estructura molecular 
de 319 fármacos utilizando el programa HyperChem. Los descriptores computa-
cionales fueron relacionados matemáticamente contra los respectivos valores LD50 
tomados de la literatura. Para evaluar la precisión del modelo QSTR propuesto se 
utilizaron el coeficiente de correlación (R), el valor F y el porcentaje de desviación 
promedio (APD) entre los valores calculados y experimentales de LD50. El mejor 
modelo QSTR es: 
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Donde, SAA es el área superficial (aproximada), VOL es el volumen molar, HE es 
la energía de hidratación, log P es el logaritmo del coeficiente de reparto, REF es 
la refractividad molar, POL es la polarizabilidad, MASS es la masa molar, TE es la 
energía total y HOMO es la energía del orbital molecular más altamente ocupado. 
El valor de APD de un cierto número de fármacos es muy alto y esto incidió en un 
alto valor de APD para el total de compuestos estudiados. Estos fármacos incluyeron 
busulfán, calcitriol, epinefrina, triaziquona, entre otros, por lo que fueron conside-
rados como descartables. Después de excluir estos puntos, el modelo obtenido es:
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Con algunos pequeños cambios en las constantes el modelo demostró ser robusto y 
por lo tanto se consideró como altamente predictivo. El alto valor de APD obtenido 
podría justificarse gracias a los diferentes mecanismos de toxicidad y a la gran disper-
sión de los valores de LD50 presentados en la literatura. Como ejemplo podría citarse 
el caso de la dixirazina, para la cual se han reportado valores de LD50 de 37,5 y 3,75 
según las diferentes fuentes bibliográficas. Después de excluir esos compuestos, el 
valor APD se reduce a 977%, el cual podría considerarse como aceptable si se tienen 
en cuenta las discrepancias experimentales encontradas en los valores de LD50 que 
han sido reportados por diferentes laboratorios.
Palabras clave: Correlaciones cuantitativas estructura-toxicidad, Ratas, Fármacos, 
LD50.
Introduction
The first step in the development of a new drug is the synthesis of a potential new drug 
molecule or extraction of a candidate chemical compound from natural sources. The 
safety and efficacy of a drug have to be investigated before its marketing. These inves-
tigations start from in vitro studies and continue for most of the biologic effects of the 
molecule which should be characterized in animal studies before human drug trials. 
Human testing must then go forward in three conventional phases before the drug is 
considered for final approval of marketing. A fourth phase of data gathering follows 
after approval for general use. 
Enormous costs, from 100 million to over 500 million USD, are involved in the deve-
lopment of a successful new drug. These costs are spent for searching new molecules 
and a huge number of candidates (5000-10000) may be synthesized for each successful 
drug, basic and clinical studies and promotion of the ultimate candidate molecule. It is 
primarily because of the economic investment and risks involved that most of the new 
drugs are now developed in the laboratories of pharmaceutical companies. At the same 
time, the incentives to succeed in drug development are equally enormous (1).
It is important to recognize the limitations of preclinical testing. These include the fol-
lowing: (A) Toxicity testing is time-consuming and expensive. During the last decade, 
the total cost of preclinical pharmacology and toxicology studies was estimated to be 
at least 41 million USD per a successful drug and 2-5 years to collect and analyze data. 
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(B) Large numbers of animals are used to obtain preclinical data and there are limi-
tations for animal studies in some societies. Scientists are properly concerned about 
this situation, and progress has been made toward reducing the number of animals 
required while still obtaining valid data. In vitro methods such as cell and tissue cul-
tures are increasingly being used, but their predictive capacity is still severely limited. 
(C) Extrapolation of toxicity data from animals to humans is not completely reliable. 
For any given compound, the total toxicity data from all species have a very high pre-
dictive value for it’s toxicity in human. However, there are limitations on the extent of 
the available databases. (D) For statistical reasons, rare adverse effects are unlikely to be 
detected, just as in clinical trials (2).
Finding an active compound with maximal pharmacologic effects and minimal adverse 
and toxic effects is the most important goal of drug development investigations. 
Different mechanisms are involved in the toxicity of a compound and the tools on 
understanding such a complex phenomena are still very limited. Although different 
mechanisms are effective and different receptors are involved in toxic responses, but 
the outcomes of toxicity are death; disability and/or mutations.
The severe adverse and toxic effects result in decreasing the chance of further progress 
of introduction of the new drugs. In addition to the experimental investigations, the 
computational methods could also be employed in order to determining the safety and 
efficacy of the new candidates. By considering that drugs toxic effects result from their 
physico-chemical reactions with biological systems, basically, there must exist a rela-
tionship between physico-chemical characteristics of drugs and their toxic effects. 
This relationship could be determined for the kinetic or dynamic effects of physico-
chemical properties of drugs. Statistical analyses of drug data, for correlating toxicity 
with chemical structure and proposing mathematical models with ability of toxicity 
prediction, makes the drug discovery investigations faster and more cost-effective. 
These models could be applied for predicting toxicity of new compounds based on 
their structures (3).
Quantitative structure – activity (QSARs) and quantitative structure – toxicity 
(QSTRs) relationships have provided a valuable approach in research into the toxicity 
of organic chemicals in such studies (4).
One and two parameter QSTR equations were obtained to describe the cytotoxicity 
of isolated rat hepatocytes induced by 23 catechols in which LD50 represents the cat-
echol concentration required to induce 50% toxicity after 2 h incubation. The reported 
QSTR equation was:
A QSTR of drugs on rat
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where log P represents the logarithm of octanol/water partition coefficient.
Excluding three catechols from the original data set improved the QSTR equation 
between the catechols log LD50 (M, 2h) and their log P values. The presence of outlir-
ers implies that factors or specific mechanisms other than log P are involved in their 
cytotoxicity. Therefore, they obtained the two–parameter QSTR equation in order to 
describe the correlation between the cytotoxicity of the various catechols, their lipophi-
licity (log P) and their degree of ionization (pKa1) towards isolated rat hepatocytes: 
log . . . . log . .LD M P p50 4 389 0 350 0 343 0 058 0 116 0 041( ) = ±( )− ±( ) − ±( ) K
N R S E p
a1
22 0 738 0 375                             = = =, . , . . . , < 0 01.
 (Eq. 2)
Moridani et al. (5) excluded one catechol from the data set and improved the QSTR 
equation between the catechols log LD50 (M, 2h), and physico–chemical properties 
log P and pKa1 values. QSTR models can be used as a powerful tool for understanding 
the toxic mechanisms that may be common among a group of similar compounds such 
as catechols. This is possible by first deriving the QSTR equations correlating differ-
ent physico–chemical parameters to catechol toxicity. Then these QSTR equations 
can be applied to other biological endpoints that contribute to the toxic mechanisms; 
i.e., transport, metabolism, and target damage, so as to determine which endpoint is 
affected by the same catechol physico-chemical parameters that contribute to the tox-
icity. This information would be valuable to a research group that uses catechol func-
tional groups for drug design and the optimization of a catechol molecule for a desired 
physico – chemical characteristic (5). 
In another investigation on LD100 of some drugs in human subjects, the following rela-
tion was reported: 
log . log . .
, . , .
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LD100 data of drugs were collected by measuring blood concentration of drugs obtained 
from the suicides victims. In Eq. 3 NVE is the number of valence electrons. To fur-
ther improve Eq. 3, the toxicity data of 41 different drugs were applied and Eq. 4 was 
reported:
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In this model, five drugs were considered as outliers and removed to improve the QSTR 
model between LD100, NVE and log P. Drugs with Cl and Br substitutions fit well with 
this equation. In two recent models log P is one of the parameters that is determining 
the absorption of drugs from gastrointestinal tract and also drug penetration to the 
CNS (6).
The aim of the present study is to provide a model for prediction of drug toxicity based 
on acute toxicity data (LD50) on rats and extend this model for toxicity evaluation of 
new drug candidates.
Materials and Methods
Toxicity data (LD50 mg/kg) of drugs (N=319) on rat after intravenous administra-
tion were collected from the literature (7-9). Then physico-chemical descriptors of the 
molecules were calculated using HyperChem® software (10). These descriptors were: 
surface area approximate (SAA), molecular weight (MASS), molar volume (VOL), 
total energy (TE), hydration energy (HE), molar refractivity (REF), logarithm of par-
tition coefficient (log P), polarizability (POL), dipole moment (DM) and energy of 
the highest occupied molecular orbital (HOMO).
Details of the collected data including the drug name, LD50 values and the calcu-
lated descriptors are listed in Table 1. LD50 was used as dependent variable and other 
descriptors as independent variables and the best equation with consideration of cor-
relation coefficient (R), percentage deviation (PD), F value and average percentage 
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where, N is the number of data points. All calculations were carried out in SPSS (11) 
environment using the written programs through this project.
Table 1. List of studied drugs, their LD50 values in rat after intravenous administration and compu-
tational parameters calculated by HyperChem. 
No. Name LD50 SAA VOL HE Log P REF POL MW
1 Acarbose 7400.0 598.81 1492.52 –33.10 –5.36 134.09 54.57 631.58
2 Aceclidine 45.0 289.68 557.87 0.40 0.16 45.38 17.81 169.22
3 Acetylcycteine 1140.0 328.46 501.74 –8.24 –0.91 37.61 15.11 163.19
4 Aciclovir 910.0 334.75 649.21 –19.08 –1.45 54.54 20.99 225.21
5 Adiphenine 27.0 538.55 1006.14 –1.60 4.15 94.32 36.85 311.42
6 Ajmaline 26.0 303.17 883.79 –3.51 2.70 92.56 36.23 326.44
7 Alimemazine 35.0 439.45 897.49 –1.06 3.80 93.37 36.03 298.45
8 Aminocaproicacid 3300.0 340.38 496.13 –8.89 0.15 34.66 13.86 131.17
9 Aminophenazone 98.0 519.16 842.41 –1.08 –0.03 70.11 26.45 231.30
10 Ampicillin 6200.0 438.85 940.77 –13.19 0.14 87.43 35.18 349.40
11 Amrinone 75.0 287.52 566.77 –11.76 –2.96 56.65 20.53 187.20
12 Ancitabine 820.0 212.38 600.02 –12.85 –0.20 51.69 20.54 225.20
13 Astemizole 28.2 614.21 1322.88 –7.20 5.64 134.69 52.09 458.58
14 Atenolol 77.0 502.33 877.04 –11.47 0.56 73.50 29.18 266.34
15 Atropine 73.0 388.21 865.40 –6.14 1.71 80.81 31.76 289.37
16 Azapropazone 660.0 468.72 889.03 –1.99 3.09 83.63 32.39 300.36
17 Azelastine 36.0 513.30 1080.06 –1.29 4.05 110.02 42.55 381.90
18 Azosemide 252.0 329.85 836.20 –17.76 1.78 98.91 32.62 370.83
19 Aztreonam 2001.0 454.75 1000.14 –18.08 –0.53 95.13 35.12 435.43
20 Baclofen 78.0 345.75 627.62 –10.19 1.50 54.83 21.78 213.66
21 Bamethan 80.0 447.90 732.22 –11.86 2.12 60.84 24.07 209.29
22 Beclamide 770.0 445.86 728.76 –2.13 2.64 62.37 24.81 225.72
23 Bemegride 16.0 324.29 507.92 –2.28 0.48 40.51 16.20 155.20
24 Bendazac 304.0 377.36 811.94 –11.76 3.02 77.15 30.30 282.30
25 Benperidol 21.0 513.33 1081.21 –4.70 2.37 106.35 41.03 381.45
26 Bentiromide 485.0 572.55 1137.75 –19.76 3.37 109.68 43.16 404.42
27 Benzoctamine 36.0 310.45 772.99 –1.80 3.81 79.45 30.91 249.36
(Continued)
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Table 1. List of studied drugs, their LD50 values in rat after intravenous administration and compu-
tational parameters calculated by HyperChem (continuation).
No. Name LD50 SAA VOL HE Log P REF POL MW
28 Benzthiazide 422.0 530.39 1017.93 –13.21 –1.12 108.39 35.67 431.93
29 Benzyl alcohol 53.0 250.83 406.36 –6.21 1.51 32.87 12.91 108.14
30 Bevantolol 38.0 632.78 1106.75 –10.91 3.03 98.54 38.67 345.44
31 Bifonazole 63.0 425.06 955.39 –6.14 4.58 98.94 38.41 310.40
32 Binedaline 27.0 532.28 959.36 –1.28 2.26 93.39 36.03 293.41
33 Bromperidol 10.0 542.58 1063.73 –4.18 3.65 105.41 40.44 420.32
34 Budesonide 98.9 500.88 1149.25 –9.04 3.28 116.15 45.12 430.54
35 Budipine 28.0 450.41 929.06 –0.14 4.91 95.15 37.19 293.45
36 Bufetolol 59.4 531.61 1000.36 –5.20 1.85 89.73 35.58 323.43
37 Bupiracaine 5.6 472.84 934.92 0.61 3.82 88.41 34.47 288.43
38 Buperenorphine 31.0 481.70 1230.03 –5.75 3.96 131.47 51.89 467.65
39 Busulfan 1.8 527.53 680.54 –8.86 –0.11 50.31 15.33 246.29
40 Caffeine 105.0 337.43 569.16 –2.33 –1.06 50.01 18.87 194.19
41 Calcitriol 0.1 625.14 1287.88 –6.85 4.53 126.53 49.33 416.64
42 Captopril 554.0 364.23 645.63 –4.54 0.30 54.73 21.67 217.28
43 Carboquone 3.6 447.47 912.16 –5.68 –1.17 83.51 31.18 321.33
44 Carbromal 427.0 383.67 591.59 –6.62 1.03 48.70 19.12 237.10
45 Carbutamide 980.0 474.65 798.28 –10.32 0.96 69.93 24.89 271.33
46 Carbuterol 77.2 474.44 830.43 –17.71 0.33 72.53 28.69 267.33
47 Carisoprodol 450.0 515.21 837.41 –4.12 1.96 67.10 26.94 260.33
48 Carpipramine 37.0 522.43 1299.50 –3.61 3.37 136.14 52.62 446.64
49 Carvedilol 25.0 565.54 1190.58 –14.89 –2.39 128.52 45.24 406.48
50 Chenodeoxycholic acid 106.0 428.39 1099.29 –5.92 4.27 109.27 43.72 392.58
51 Chloramphenicol 171.0 465.84 806.44 –16.35 1.28 73.18 28.02 323.13
52 Chlorazanil 16.0 311.21 627.34 –13.85 2.85 58.05 22.60 221.65
53 Chlordiazepoxide 165.0 451.52 875.09 –4.62 5.26 88.91 34.27 313.79
54 Chlorhexidine 21.0 739.82 1475.30 –27.42 6.59 137.68 54.14 505.45
55 Chlorpyramine 32.5 497.46 887.11 –1.68 3.14 87.88 33.19 289.81
56 Chloroquine 60.0 591.61 1017.45 –2.31 2.53 97.62 36.96 299.46
57 Chlorothiazide 200.0 355.30 639.73 –13.84 –3.26 67.07 19.33 295.72
(Continued)
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Table 1. List of studied drugs, their LD50 values in rat after intravenous administration and compu-
tational parameters calculated by HyperChem (continuation).
No. Name LD50 SAA VOL HE Log P REF POL MW
58 Chlorphenesin carbamate 236.0 449.15 712.62 –7.22 2.69 59.45 23.63 265.09
59 Chlorpromazine 23.0 504.31 905.72 –1.27 3.82 93.76 36.13 318.86
60 Chlorpropamide 590.0 470.91 755.46 –6.49 1.87 65.43 23.63 276.74
61 Chlorteracycline 118.0 494.02 1118.49 –21.81 –1.69 118.13 45.16 478.89
62 Cimetidine 106.0 492.66 798.81 –15.34 –0.59 72.48 27.10 252.34
63 Cinnarizine 24.0 504.85 1127.92 –3.41 5.89 119.86 46.17 368.52
64 Cinoxacin 900.0 357.42 700.48 –11.71 –0.34 66.77 24.26 262.22
65 Ciprofloxacin 207.0 425.24 898.64 –6.98 0.67 87.15 32.88 331.35
66 Clebopride 39.0 478.24 1045.88 –8.27 2.36 105.57 40.70 373.88
67 Clobutinol 63.0 462.52 792.54 –1.28 2.96 74.04 29.03 255.79
68 Clorexolone 120.0 460.12 879.69 –4.77 –0.47 85.35 29.42 328.81
69 Cloricromen 10.0 665.51 1134.88 –2.80 2.79 104.81 40.52 395.88
70 Clozapine 41.6 434.30 925.09 –3.01 –0.73 103.53 36.47 326.83
71 Codeine 75.0 317.87 828.61 –4.15 1.57 84.60 32.43 299.37
72 Convallatoxin 15.2 548.66 1370.14 –14.26 0.28 136.78 54.42 550.65
73 Creatinolfosfate 1300.0 356.20 563.10 –25.12 0.29 42.10 14.62 197.13
74 Cyclobutyrol 1760.0 316.50 602.23 –4.83 1.74 49.12 19.71 186.25
75 Cyclophosphamide 148.0 385.46 677.38 –2.49 1.12 58.48 21.00 261.09
76 Dacarbazine 411.0 343.70 576.38 –14.40 –0.92 51.20 17.95 182.18
77 Daunorubicin 13.0 550.76 1306.79 –17.94 –2.40 137.10 51.37 527.53
78 Dehydrocholic acid 750.0 499.87 1089.67 –3.52 4.46 108.01 42.70 402.53
79 Deserpidine 15.0 728.50 1575.97 –8.93 1.65 155.39 60.20 578.66
80 Desipramine 29.0 430.98 868.60 –3.18 3.64 85.31 33.03 266.69
81 Dextromethrophan 16.3 342.36 820.17 –0.88 3.35 82.56 32.12 271.40
82 Dextromoramide 13.0 438.79 1101.81 –2.38 3.81 117.49 45.83 392.54
83 Dibenzepine 22.0 455.17 907.09 –0.82 3.40 90.46 34.95 294.40
84 Dichlorophen 17.0 365.58 713.74 –11.71 4.59 68.79 27.06 269.13
85 Dimetindene 27.0 466.14 942.17 –0.74 2.49 100.32 36.28 292.42
86 Dinoprost 106.0 577.70 1080.76 –14.52 3.10 100.47 38.95 354.49
87 Dinoprostone 59.5 626.83 1116.94 –8.23 3.67 99.43 38.40 352.47
(Continued)
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Table 1. List of studied drugs, their LD50 values in rat after intravenous administration and compu-
tational parameters calculated by HyperChem (continuation). 
No. Name LD50 SAA VOL HE Log P REF POL MW
88 Diphenhydramine 42.0 485.89 860.33 –1.80 3.62 79.93 31.26 255.36
89 Diprophylline 860.0 406.14 714.68 –11.58 –1.88 62.26 23.82 254.25
90 Dipyridamole 195.0 613.97 1387.93 –20.12 2.09 139.51 53.21 504.63
91 Disopyramide 39.1 505.64 1041.41 –4.10 2.30 106.79 40.52 339.48
92 Dixyrazine 37.5 601.47 1231.36 –8.99 –0.86 136.19 48.89 427.60
93 Domperidone 41.7 485.04 1118.86 –7.30 –2.73 125.16 44.98 425.92
94 Doxepin 16.0 455.99 887.14 –2.06 3.57 89.07 33.96 279.38
95 Doxofylline 315.0 403.37 741.74 –4.22 –1.23 64.86 24.88 266.26
96 Doxorubicin 10.5 575.19 1321.78 –24.05 0.17 134.02 52.00 543.53
97 Doxycycline 228.0 461.24 1084.23 –21.47 –1.86 113.03 43.23 444.44
98 Epinephrine 0.2 346.74 587.50 –19.31 –1.61 52.62 19.20 183.21
99 Epirizole 214.0 395.42 716.43 –5.31 1.86 64.61 24.45 234.26
100 Ergotamine 80.0 540.48 1451.82 –8.10 0.24 163.75 61.89 581.67
101 Etamivan 17.0 317.39 695.02 –7.79 1.52 62.09 24.15 223.27
102 Ethinamate 157.0 328.94 558.72 –5.34 1.19 44.57 17.48 167.21
103 Ethylmorhine 62.0 363.24 879.67 –7.26 1.95 88.53 34.26 313.40
104 Etodroxizine 58.0 651.90 1235.17 –10.06 3.33 118.12 46.05 418.96
105 Etofenamate 139.0 574.32 997.91 –11.81 3.30 89.38 34.18 369.34
106 Etomidate 14.8 386.68 755.14 –2.99 1.31 70.73 27.16 244.29
107 Etoposide 75.0 638.50 1444.77 –22.89 1.27 138.73 55.15 588.56
108 Felodipine 5.4 535.56 1005.32 –2.53 1.81 99.49 37.95 384.26
109 Fencarbamide 30.0 551.08 1019.30 –1.39 4.46 99.40 38.73 328.47
110 Fentanyl 2.9 533.76 1070.16 –1.32 3.77 103.48 40.46 336.48
111 Fleroxacin 20.4 491.35 932.62 –5.32 –2.32 93.02 33.47 369.34
112 Floctafenine 160.0 507.55 1035.19 –16.33 2.10 100.96 37.82 406.36
113 Flopropione 246.0 305.94 543.12 –14.26 1.13 46.17 17.94 182.18
114 Fluanisone 20.0 536.07 1049.28 –1.86 3.50 102.57 39.17 356.44
115 Flufenamic acid 98.0 353.20 730.27 –8.55 3.88 67.28 25.56 281.23
116 Flumazenil 85.0 436.62 830.39 –3.11 0.23 79.96 29.56 303.29
117 Fluorouracil 245.0 234.76 356.26 –6.59 –1.78 26.20 9.93 130.08
118 Flurazepam 38.7 564.41 1092.61 –0.62 3.81 107.54 41.39 387.88
(Continued)
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Table 1. List of studied drugs, their LD50 values in rat after intravenous administration and compu-
tational parameters calculated by HyperChem (continuation).
No. Name LD50 SAA VOL HE Log P REF POL MW
119 Fosfestrol 425.0 579.69 1120.90 –28.81 5.62 103.84 36.65 428.32
120 Furosemide 800.0 433.99 813.52 –14.68 0.00 80.76 27.41 330.74
121 Gefarnate 2040.0 985.90 1464.24 5.38 7.25 131.77 50.08 400.64
122 Gliclazide 382.0 473.27 918.42 –6.01 1.90 83.88 30.68 323.41
123 Glisoxepide 196.0 499.89 1145.50 –12.52 1.67 116.80 42.67 449.52
124 Glyconiazide 1763.0 385.70 786.36 –20.97 –2.63 69.39 26.80 295.25
125 Griseofulvin 400.0 477.79 915.00 –6.00 1.18 87.58 33.53 352.77
126 Guaifenesin 360.0 366.36 631.93 –14.00 0.73 51.24 20.32 198.22
127 Haloperidol 15.0 553.08 1058.52 –4.09 3.38 102.59 39.75 375.87
128 Hexobendine 34.0 1003.16 1800.50 –9.27 1.92 157.75 61.09 592.69
129 Hydralazine 34.0 248.85 504.04 –17.29 1.87 48.23 17.90 160.18
130 Hydroxyzine 45.0 568.06 1130.91 –8.87 3.49 107.07 41.74 374.91
131 Ibudilast 42.5 377.75 731.77 –1.05 2.82 72.04 26.71 230.31
132 Ifosfamide 190.0 427.29 701.32 –3.02 1.12 58.48 21.00 261.09
133 Imipenem 1972.0 464.34 844.96 –18.04 –2.65 76.08 29.14 299.34
134 Imipramine 9.3 467.69 912.65 –0.01 4.01 90.61 34.87 280.41
135 Indecainide 10.0 470.46 973.06 –5.40 3.36 94.17 36.79 308.42
136 Indobufen 333.0 438.71 872.77 –5.90 3.37 83.25 32.49 295.34
137 Indometacin 21.0 500.18 958.41 –10.03 2.31 95.25 36.70 357.79
138 Inositol nicotinate 268.0 748.87 1914.86 –20.08 –3.28 215.21 80.06 810.73
139 Iocarmic acid 13300.0 967.86 1731.25 –20.14 7.64 200.65 79.48 1253.87
140 Iocetamic acid 700.0 510.31 913.42 –8.84 4.42 101.32 40.04 613.96
141 Iopanoic acid 280.0 467.98 836.93 –7.14 6.02 93.07 36.77 570.94
142 Iotroxic acid 4190.0 993.21 1743.20 –18.99 7.83 188.23 74.84 1215.82
143 Ioxaglic acid 13300.0 985.79 1759.22 –20.02 5.79 204.55 80.83 1268.89
144 Isoniazid 365.0 249.32 449.40 –14.68 –1.37 39.69 14.35 137.14
145 Isoprenaline 57.0 408.16 692.27 –17.54 1.39 57.82 22.87 211.26
146 Isosorbide mononitrate 1750.0 297.93 512.41 –14.63 –0.26 38.08 14.63 191.14
147 Isradipine 1.8 494.65 1021.85 –7.48 1.98 102.60 37.85 371.39
148 Itraconazole 40.0 850.24 1843.15 –8.43 7.59 189.98 73.26 705.64
(Continued)
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Table 1. List of studied drugs, their LD50 values in rat after intravenous administration and compu-
tational parameters calculated by HyperChem (continuation).
No. Name LD50 SAA VOL HE Log P REF POL MW
149 Kanamycin 437.0 357.10 1193.22 –32.11 –5.63 106.13 43.89 484.50
150 Kebuzone 315.0 467.31 942.31 –3.50 3.14 89.37 35.13 322.36
151 Ketobemidone 10.0 410.19 773.70 –6.40 2.98 72.84 28.25 247.34
152 Ketoconazole 86.0 630.23 1369.53 –5.03 3.55 139.07 54.11 531.44
153 Ketoprofen 350.0 399.05 768.53 –8.58 3.46 72.52 28.24 254.29
154 Khellin 34.4 368.03 725.10 –6.44 –3.33 72.86 25.82 260.25
155 Levamisole 24.0 303.11 625.84 –2.52 2.79 60.02 23.35 204.29
156 Lidocaine 18.0 355.85 782.43 –1.79 2.38 72.15 27.90 234.34
157 Lofexidine 13.0 366.23 708.83 –3.79 2.86 64.41 25.61 259.14
158 Loperamide 5.1 589.25 1309.10 –5.65 5.01 139.44 54.52 477.05
159 Loxapine 18.0 439.39 912.84 –4.27 3.62 92.60 35.76 327.81
160 Maprotiline 38.0 394.67 881.24 –2.59 4.00 91.60 34.77 279.43
161 Mefenamic acid 112.0 376.86 730.88 –5.19 3.93 71.39 27.67 241.29
162 Mefruside 500.0 517.46 923.15 –7.55 0.77 89.05 30.05 382.88
163 Melphalan 4.1 493.46 858.14 –9.73 2.82 78.23 30.56 305.20
164 Mephenesin 133.0 358.28 607.10 –12.47 1.45 49.82 19.68 182.22
165 Meprobamate 350.0 422.01 695.41 –8.57 0.96 53.04 21.44 218.25
166 Meproscillarin 5.8 584.50 1415.64 –9.51 2.51 144.84 56.98 544.69
167 Mercaptopurine 250.0 210.78 428.52 –12.60 –0.44 42.91 16.02 152.17
168 Methotrexate 14.0 582.62 1226.75 –28.45 0.53 116.88 45.06 454.45
169 Methylergometrine 23.0 480.54 1006.43 –9.83 0.39 99.87 38.19 339.44
170 Methylphenidate 48.0 371.86 748.11 –3.17 2.12 66.73 26.41 233.31
171 Methyprylon 380.0 329.98 588.51 –1.59 2.09 50.25 19.87 183.25
172 Meticrane 445.0 371.54 680.50 –7.43 0.92 66.11 20.63 275.34
173 Metoprolol 71.9 581.88 920.06 –7.92 1.79 76.70 30.21 267.37
174 Mexiletine 41.0 348.21 633.12 –2.42 2.35 54.97 21.60 179.26
175 Miconazole 105.0 558.06 1038.37 –4.87 4.81 104.07 40.77 416.13
176 midazolam 75.0 376.13 869.82 –3.18 3.41 91.20 34.42 325.77
177 Milrinone 73.0 357.72 632.12 –9.95 –1.49 63.86 22.87 211.22
178 Minoxidil 49.0 303.34 641.66 –12.56 2.23 57.30 22.10 209.25
179 Mitomycin 3.0 369.81 868.49 –11.49 –1.42 83.27 31.75 334.33
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Table 1. List of studied drugs, their LD50 values in rat after intravenous administration and compu-
tational parameters calculated by HyperChem (continuation).
No. Name LD50 SAA VOL HE Log P REF POL MW
180 Mizoribine 1500.0 272.75 665.58 –20.72 –2.57 56.75 22.46 259.22
181 Moracizine 11.0 523.59 1137.34 –5.85 –2.53 126.45 45.40 427.52
182 Morphine 140.0 288.45 776.75 –9.00 1.53 79.83 30.59 285.34
183 Mupirocin 1310.0 778.04 1462.83 –17.15 2.32 129.39 51.38 500.63
184 Nadolol 59.2 521.31 960.91 –14.76 1.27 85.52 33.74 309.41
185 Nalidixic acid 88.4 365.25 682.96 –5.36 0.33 64.85 23.76 232.24
186 Nalorphine 226.0 333.53 853.86 –12.63 2.27 89.00 34.07 311.38
187 Nemonapride 17.0 551.12 1106.09 –6.58 3.08 110.61 42.54 387.91
188 Netilmicin 25.2 544.16 1291.99 –19.73 –4.08 114.83 46.17 461.56
189 Nicergoline 42.0 562.12 1202.54 –3.61 0.39 125.81 47.41 484.39
190 Nikethamide 191.0 356.57 594.47 –1.65 –0.05 54.57 20.34 178.23
191 Nilvadipine 9.7 579.93 1045.08 –11.44 0.92 102.09 37.79 385.38
192 Nimodipine 5.0 595.49 1160.47 –7.37 0.97 112.67 42.08 418.45
193 Nipradilol 78.0 532.94 948.65 –15.02 2.01 82.80 31.91 326.35
194 Nisoldipine 1.1 481.75 1074.82 –3.76 1.60 106.20 39.60 388.42
195 Nitrendipine 12.6 527.58 979.60 –7.08 0.72 97.21 35.93 360.37
196 Nizatidine 301.0 617.91 978.65 –11.43 –1.00 90.52 34.46 331.45
197 Norfenefrine 17.4 284.15 516.19 –16.91 0.51 42.19 16.73 153.18
198 Norfloxacin 245.0 445.45 872.54 –7.47 0.62 84.68 31.81 319.34
199 Nortriptyline 22.0 426.22 865.42 –3.40 4.16 87.04 33.32 263.38
200 Oleandomycin 440.0 728.55 1696.72 –10.77 2.94 173.69 69.80 687.87
201 Opipramol 32.0 492.56 1103.11 –6.09 3.36 112.95 43.42 365.52
202 Orciprenaline 67.2 417.28 692.61 –17.95 1.39 57.82 22.87 211.26
203 Oxaprozin 82.0 440.91 875.94 –10.07 2.13 84.03 32.43 293.32
204 Oxatomide 29.0 511.15 1232.85 –5.81 4.21 129.16 50.21 426.56
205 Oxitriptan 27.0 330.44 652.59 –19.29 –0.23 58.19 22.70 220.23
206 Oxyphenbutazone 68.0 463.63 951.83 –9.47 3.94 90.45 35.68 324.38
207 Oxytetracycline 260.0 457.06 1091.59 –22.73 –2.98 114.54 43.87 460.44
208 Ozagrel 1150.0 378.31 667.13 –10.07 1.51 62.51 23.29 214.22
209 Pantethine 3410.0 942.20 1576.46 –25.11 –1.94 139.50 55.44 554.72
210 Papaverine 13.3 446.29 1096.29 –7.82 2.26 97.42 37.29 339.39
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Table 1. List of studied drugs, their LD50 values in rat after intravenous administration and compu-
tational parameters calculated by HyperChem (continuation).
No. Name LD50 SAA VOL HE Log P REF POL MW
211 Penbutolol 22.0 533.28 968.27 –3.27 3.36 86.60 34.30 291.43
212 Penicillamine 2000.0 289.16 464.57 –9.31 –0.24 37.22 15.02 149.21
213 Pentazocine 21.0 446.52 895.35 –4.69 4.28 89.51 34.54 285.43
214 Pentetrazol 45.0 245.42 452.75 –11.90 2.12 41.35 14.58 138.17
215 Pentoxifylline 231.0 503.55 840.05 –1.21 –0.14 73.70 28.13 278.31
216 Perazine 80.0 466.71 980.29 –1.65 3.10 105.00 40.28 339.50
217 Periciazine 35.0 482.59 1032.89 –9.59 2.89 108.41 41.42 365.49
218 Perlapine 60.0 405.98 891.20 –2.36 3.76 91.29 35.03 291.40
219 Perphenazine 34.0 552.77 1120.84 –7.40 3.18 116.10 44.68 403.97
220 Pethidine 22.5 406.54 784.21 –0.79 2.47 72.48 28.25 247.34
221 Phenobarbital 209.0 326.94 650.14 –7.34 1.56 59.75 23.63 232.24
222 Phenylbutazone 100.0 461.79 940.17 –2.50 4.22 88.76 35.04 308.38
223 Phenytoin 101.0 330.43 723.73 –7.53 2.26 69.98 27.70 252.27
224 Pilsicainide 18.0 386.24 837.41 –0.22 2.34 81.99 31.86 272.39
225 Pimobendan 72.0 484.26 982.19 –12.44 2.70 94.90 36.68 334.38
226 Pimozide 90.0 567.26 1272.37 –5.12 5.38 130.43 50.51 461.55
227 Pinacidil 155.0 362.27 763.47 –9.72 2.00 74.56 28.06 245.33
228 Pindolol 51.0 451.99 812.85 –11.09 1.01 72.52 28.12 248.32
229 Pipamperone 48.0 493.64 1071.90 –2.88 1.15 105.10 40.55 375.49
230 Pipemidic acide 529.0 423.88 851.01 –9.11 0.30 80.11 30.49 303.32
231 Piperidolate 100.0 492.16 1012.61 –2.01 4.21 96.78 37.91 323.43
232 Pipradrol 30.0 341.55 824.01 –4.24 3.50 81.58 32.32 267.37
233 Piretanide 700.0 572.93 1008.97 –12.47 2.65 94.37 33.69 362.40
234 Piritramide 13.0 527.13 1237.88 –7.56 3.49 129.31 50.23 430.59
235 Piromidic acid 158.0 409.97 824.06 –5.50 1.19 76.90 29.14 288.31
236 Pivampicillin 148.0 644.39 1270.78 –8.78 2.08 116.15 46.92 463.55
237 Plaunotol 120.0 420.56 948.93 –11.95 2.45 98.49 37.91 360.45
238 Procainamide 110.0 477.59 809.36 –5.59 1.01 71.75 27.42 235.33
239 Procaine 42.0 477.53 798.72 –4.60 1.66 69.80 26.70 236.31
240 Profenamine 15.0 421.81 936.93 –0.81 4.35 98.00 37.87 312.47
241 Promazine 14.5 466.96 861.70 –1.53 3.30 88.95 34.20 284.42
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Table 1. List of studied drugs, their LD50 values in rat after intravenous administration and compu-
tational parameters calculated by HyperChem (continuation).
No. Name LD50 SAA VOL HE Log P REF POL MW
242 Promethazine 45.0 426.13 831.88 –1.60 3.66 88.50 34.20 284.42
243 Propanidid 81.0 494.26 1071.38 –9.92 1.87 91.53 35.89 337.42
244 Propentofylline 180.0 563.86 944.53 –0.10 0.67 82.97 31.80 306.36
245 Propofol 42.0 358.50 637.27 –1.59 4.15 56.13 22.08 178.27
246 Propranolol 23.0 472.91 856.84 –7.11 1.76 80.00 30.25 259.35
247 Prosicllaridin 9.0 510.89 1350.47 –14.32 2.23 140.08 55.15 530.66
248 Prothipendyl 25.0 457.73 856.01 –2.23 –0.34 94.26 33.49 285.41
249 Protirelin 514.0 291.23 525.70 –15.98 –2.45 46.97 17.14 169.18
250 Proxyphylline 430.0 580.65 974.58 –3.24 2.22 85.54 32.85 294.39
251 Pyridoxine (vitamin B6) 657.0 291.23 525.70 –15.98 –2.45 46.97 17.14 169.18
252 Quazepam 2749.0 441.15 903.46 –3.03 5.24 93.76 35.59 386.79
253 Quinidine 23.0 404.99 942.51 –7.47 1.96 96.76 36.98 324.42
254 Ranimustine 31.8 406.58 824.94 –15.47 –0.78 70.05 27.46 327.72
255 Ranitidine 93.0 601.96 962.89 –11.30 –1.18 88.40 32.81 314.40
256 Rebamipide 700.0 488.64 978.63 –12.38 2.22 96.22 37.50 370.79
257 Reserpine 15.0 761.01 1622.98 –11.28 1.40 161.85 62.67 608.69
258 Riboflavin ( Vit B2) 50.0 506.91 994.61 –18.27 1.51 93.63 36.36 376.37
259 Ribostamycin 535.0 384.14 1112.84 –28.98 –4.72 99.99 41.42 454.48
260 Risperidone 26.9 460.78 1109.07 –3.92 1.94 114.61 43.54 410.49
261 Salazosulfapyridine 1520.0 541.71 1041.18 –25.59 3.57 106.34 36.79 398.39
262 Salbutamol 57.1 468.72 778.27 –14.60 1.21 67.58 26.54 239.31
263 Secobarbital 80.0 360.39 627.54 –4.86 1.47 53.40 21.31 212.25
264 Sisomicin 32.0 473.05 1219.63 –20.90 –4.49 110.05 44.34 447.53
265 Sofalcone 105.0 828.31 1378.61 –8.03 4.95 130.59 49.76 450.53
266 Spiperone 14.0 516.48 1103.63 –4.72 3.02 111.19 42.87 395.48
267 Sulfadiazine 880.0 342.67 682.45 –13.46 0.64 65.38 22.52 250.27
268 Sulfaethidole 1300.0 425.21 757.69 –17.39 2.46 72.36 25.71 284.35
269 Sulfalene 1790.0 369.29 751.43 –12.54 0.55 70.67 24.99 280.30
270 Sulfamerazine 1100.0 378.71 736.52 –11.93 1.60 69.86 24.35 264.30
271 Sulfamethizole 2710.0 395.57 708.78 –17.17 1.83 67.73 23.87 270.32
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Table 1. List of studied drugs, their LD50 values in rat after intravenous administration and compu-
tational parameters calculated by HyperChem (continuation).
No. Name LD50 SAA VOL HE Log P REF POL MW
272 Sulfametoxy diazine 1000.0 404.73 759.26 –14.98 –0.23 71.83 24.99 280.30
273 Sulfanilamide 1400.0 267.85 490.49 –11.97 0.15 44.10 14.27 172.20
274 Sulfaphenazole 525.0 359.76 829.15 –11.68 2.09 85.93 30.76 314.36
275 Sulfathiazole 1370.0 342.83 664.68 –13.55 0.63 64.97 22.75 255.31
276 Sulforidazine 24.0 403.96 1010.43 –3.27 3.24 114.52 41.90 402.57
277 Sulpiride 40.0 471.31 933.26 –8.33 0.48 89.32 32.09 341.43
278 Suprofen 226.0 393.77 742.23 –6.45 1.31 73.95 27.76 260.31
279 Suxibuzone 305.0 591.56 1223.17 –8.85 3.81 115.08 45.66 438.48
280 Tacrine 20.0 274.01 630.89 –5.72 1.83 62.62 23.82 198.27
281 Talinolol 30.0 624.37 1156.93 –8.93 2.28 102.68 40.76 363.50
282 Tazanolast 1119.0 517.22 855.23 –19.57 3.20 78.04 29.01 289.29
283 Tegafur 685.0 290.94 540.38 –4.27 –1.24 44.53 17.13 200.17
284 Terbinafine 213.0 586.26 956.27 0.54 5.34 93.79 36.66 279.43
285 Tetracaine 6.0 605.21 918.92 –1.36 2.54 79.67 30.37 264.37
286 Tetracycline 129.0 473.96 1068.17 –19.12 –1.19 111.72 42.60 428.44
287 Tetroxoprim 300.0 489.77 980.56 –16.64 0.35 89.85 34.94 334.38
288 Thenalidine 42.0 373.87 840.81 –1.05 1.91 91.98 34.39 286.43
289 Thiamphenicol 339.0 511.14 877.58 –13.31 0.47 79.61 29.15 356.22
290 Thioctic acid 180.0 382.23 621.99 –5.26 1.78 54.29 21.40 206.32
291 Thioproperazine 25.0 586.75 1182.83 –2.41 2.12 126.95 46.44 446.63
292 Thioridazine 71.0 395.17 1037.76 –1.98 4.18 113.67 43.76 370.57
293 Thiotepa 9.4 317.28 599.45 0.58 –0.54 50.72 17.63 189.22
294 Ticlopidine 70.0 275.73 683.64 –1.56 1.54 78.11 29.46 263.78
295 Tiropramide 33.9 831.48 1487.52 –1.72 4.55 138.87 54.32 467.65
296 Tobramycin 104.0 388.21 1155.59 –31.65 –5.56 106.69 43.97 467.52
297 Todralazine 110.0 386.18 703.98 –12.94 2.47 62.98 24.13 232.24
298 Tofisopam 103.0 567.31 1101.11 –9.46 4.39 109.03 42.09 382.46
299 Tolbutamide 700.0 516.65 819.67 –5.17 2.21 70.27 25.37 270.35
300 Tranexamic acid 1200.0 271.20 524.32 –7.88 0.62 41.90 16.75 157.21
301 Trazodone 91.0 510.26 1056.31 –3.24 2.80 105.91 39.94 371.87
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Table 1. List of studied drugs, their LD50 values in rat after intravenous administration and compu-
tational parameters calculated by HyperChem (continuation).
No. Name LD50 SAA VOL HE Log P REF POL MW
302 Tretinoin 78.0 606.96 1004.69 –1.89 4.73 97.79 36.46 300.44
303 Triaziquone 0.5 329.44 702.26 0.03 –1.49 66.20 23.54 231.25
304 Trichlormethiazide 920.0 442.08 785.22 –12.21 1.23 78.62 25.44 380.65
305 Trifluperidol 14.0 566.44 1084.69 –4.32 3.74 103.76 39.38 409.42
306 Trifluridine 2946.0 331.56 686.60 –8.42 –0.87 56.38 21.90 296.20
307 Trofosfamide 90.0 483.45 819.17 –0.22 1.73 72.72 26.59 323.59
308 Urapidil 140.0 564.08 1116.27 –2.40 1.30 109.45 41.95 387.48
309 Verapamil 7.3 805.46 1403.45 –7.48 5.05 132.65 51.54 454.61
310 Vesnarinone 79.3 543.75 1158.45 –6.77 1.87 110.25 42.40 395.46
311 Vidarabine 302.0 371.37 841.12 –30.74 –1.34 73.70 26.89 347.22
312 Viloxazine 60.0 337.14 723.28 –4.53 1.23 65.20 25.77 237.30
313 Vinblastine 2.0 765.55 1991.61 –6.06 1.57 227.52 86.17 810.99
314 Vincristine 1.0 767.33 1989.23 –0.76 0.19 227.00 86.25 824.97
315 Vinpocetin 32.0 409.15 993.43 0.11 2.42 106.00 39.74 350.46
316 Zimeldine 50.0 475.39 861.28 –2.82 2.52 87.56 32.34 317.23
317 Zonisamide 672.0 290.47 567.18 –11.02 0.64 51.55 17.39 212.22
318 Zopiclone 280.0 491.48 1031.64 –4.23 –1.83 101.25 37.80 368.40
319 Zotepine 36.8 521.68 942.97 –9.92 3.49 97.34 37.05 331.86
Results and Discussion
Preliminary analysis was carried out employing all independent variables by backward 
regression command of SPSS software. The resulting equation was:
 LD SAA VOL HE P50 639 254 3 773 4 786 21 050 50 753 51 4= − + − − − −. . . . . log .  40
121 219 12 932 0 011 95 494
319
 
    
REF
POL MASS TE HOMO
N
+ + + −
=
. . . .
, R F APD= = =0 748 43 2686. , , .  
 (Eq. 7)
The above equation with applying 319 experimental data of different drugs was 
resulted. Relatively high correlation coefficient (R) and F value with the significance 
level of < 0.0005 reveal that, the model is able to fit the toxicity data of drugs on rat 
after intravenous administration. APD for some data points for Eq. 7 was high because 
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of existence of the outliers which were listed in Table 2. After excluding the outlier data 
points, the resulting equation was: 
LD SAA VOL HE P50 740 217 4 050 5 138 21 909 50 713 49 6= − + − − − −. . . . . log .  62
120 843 12 742 0 010 106 513
30
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(Eq. 8)












For providing practical application of Eq. 8, Hodge and Sterner scale was applied. 
Based on this classification, drugs are divided into six groups from highly toxic to 
harmless (12). Table 3 shows the APD values for different groups and number of data 
in each group. Considering Table 3, with increasing toxicity of the drugs, predictive 
ability of the model is decreased. From statistical viewpoint, this limitation results 
from two factors: (A) Number of data in high toxic group is very small and (B) Effect 
of very small numerical values of high toxic drugs on the total LD50 mean is negligible 
and lead to the reduced accuracy of the equation.
Table 3. Toxicity classification of drugs, the number of them and APD values in each group.
Rating LD50 (mg/kg) N APD APD
High <1 4 133093 -
regular 1-50 130 2517 75
Moderate 50-500 130 269 64
Low 500-5000 51 63 48
Very low 5000-15000 4 57 -
Harmless >15000 0 - -
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In another numerical analysis, the proposed equation was trained by data of groups 
with higher than 50 data points (N>50) and then, the APD values were calculated 
and reported in Table 3. As shown, the overall APD reduces to ~ 60 %, however, one 
should be able to detect the class of the candidate concerning Hodge and Sterner clas-
sification and then to use this prediction method.
Any error in measuring or reporting the experimental toxicity data is another source 
of prediction error. In some cases, the numerical difference of the reported LD50 for a 
single drug, on a given animal and a common administration route is about 1500 folds. 
For example, LD50 of benzyl benzoate in rat after oral administration is 1.7 mg/Kg (7) 
and 2800 mg/Kg (9). The PD between two experimentally reported data is equal to 
164600 %. Table 4 shows some of different data for LD50 of drugs in rat after intrave-
nous administration. 
Table 4. Differences in the LD50 amounts reported for intravenous administration of drugs on rat.















As a conclusion, a quantitative structure toxicity relationship (QSTR) was proposed 
to correlate toxicity of drugs on rat. The proposed model is robust and could be con-
sidered as a predictive model. Because of various toxic mechanisms, high discrepancy 
in reported LD50 of some of drugs from different references, high APD value could be 
justified. After excluding the outliers, APD reduces to 977%. The APD could be con-
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sidered as acceptable error range if the experimental discrepancies between reported 
LD50 from different laboratories are kept in mind.
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